These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 22935442

  • 1. No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study.
    Giardina AR, Ferraro D, Ciccia F, Ferrante A, Di Stefano R, Craxì A, Triolo G.
    Clin Exp Rheumatol; 2013; 31(1):25-30. PubMed ID: 22935442
    [Abstract] [Full Text] [Related]

  • 2. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
    Lee YH, Bae SC, Song GG.
    Clin Exp Rheumatol; 2013; 31(1):118-21. PubMed ID: 23111095
    [Abstract] [Full Text] [Related]

  • 3. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
    Lee YH, Bae SC, Song GG.
    Int J Rheum Dis; 2013 Oct; 16(5):527-31. PubMed ID: 24164839
    [Abstract] [Full Text] [Related]

  • 4. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, Yang SS.
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [Abstract] [Full Text] [Related]

  • 5. Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies.
    Biondo MI, Germano V, Pietrosanti M, Canzoni M, Marignani M, Stroffolini T, Salemi S, D'Amelio R.
    Eur J Intern Med; 2014 Jun; 25(5):482-4. PubMed ID: 24495663
    [Abstract] [Full Text] [Related]

  • 6. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy.
    Chung SJ, Kim JK, Park MC, Park YB, Lee SK.
    J Rheumatol; 2009 Nov; 36(11):2416-20. PubMed ID: 19797507
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts.
    Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, Enomoto M, Inaba M, Nakatani T, Hino M, Kawada N.
    J Gastroenterol; 2011 Apr; 46(4):556-64. PubMed ID: 21246383
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
    Papadopoulos N, Deutsch M, Manolakopoulos S, Bitsi C, Michalakeas H, Poulakidas H, Tsironi E, Giannouli S, Papatheodoridis GV, Koskinas J, Pectasides D.
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
    [Abstract] [Full Text] [Related]

  • 11. Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report.
    Talotta R, Atzeni F, Sarzi Puttini P.
    BMC Pharmacol Toxicol; 2016 Apr 21; 17():17. PubMed ID: 27098382
    [Abstract] [Full Text] [Related]

  • 12. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.
    Mori S, Fujiyama S.
    World J Gastroenterol; 2015 Sep 28; 21(36):10274-89. PubMed ID: 26420955
    [Abstract] [Full Text] [Related]

  • 13. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs.
    Tan J, Zhou J, Zhao P, Wei J.
    Clin Rheumatol; 2012 Aug 28; 31(8):1169-75. PubMed ID: 22544263
    [Abstract] [Full Text] [Related]

  • 14. Occult hepatitis B virus infection and lamivudine-resistant mutations in isolates from renal patients undergoing hemodialysis.
    Motta JS, Mello FC, Lago BV, Perez RM, Gomes SA, Figueiredo FF.
    J Gastroenterol Hepatol; 2010 Jan 28; 25(1):101-6. PubMed ID: 19817965
    [Abstract] [Full Text] [Related]

  • 15. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases.
    Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C, Sarzi-Puttini P.
    Arthritis Care Res (Hoboken); 2010 Jun 28; 62(6):749-54. PubMed ID: 20535784
    [Abstract] [Full Text] [Related]

  • 16. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.
    Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J, Manesis EK, Archimandritis AI.
    Ann Rheum Dis; 2010 Jul 28; 69(7):1352-5. PubMed ID: 20472596
    [Abstract] [Full Text] [Related]

  • 17. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
    Varisco V, Viganò M, Batticciotto A, Lampertico P, Marchesoni A, Gibertini P, Pellerito R, Rovera G, Caporali R, Todoerti M, Covelli M, Notarnicola A, Atzeni F, Sarzi-Puttini P.
    J Rheumatol; 2016 May 28; 43(5):869-74. PubMed ID: 26879359
    [Abstract] [Full Text] [Related]

  • 18. Twenty-four year single-center experience of hepatitis B virus infection in heart transplantation.
    Chen YC, Chuang MK, Chou NK, Chi NH, Wu IH, Chen YS, Yu HY, Huang SC, Wang CH, Tsao CI, Ko WJ, Wang SS.
    Transplant Proc; 2012 May 28; 44(4):910-2. PubMed ID: 22564582
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.